StockData
Haleon plc logo

Haleon plc (HLN) stock

HLNNYSEPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31Also trades as HLNCF
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$8.66+0.09 (+1.05%)

Close on Oct 30, 2026Market cap $38.76BP/E 17.5Yield –

Earnings

Haleon's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Haleon's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Haleon has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Haleon puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Haleon filed with the SEC as exhibits to Form 8-K or 6-K

  1. Six months ended 30 June 2026
    6-K
  2. Twelve months ended 31 December 2024 (unaudited)
    6-K
  3. 6-K exhibit EX-99.1
    6-K
  4. Six months ended 30 June 2024
    6-K
  5. Three months ended 31 March 2024
    6-K
  6. PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD
    6-K
  7. Right to make off-market purchases of Ordinary Shares
    6-K
  8. Twelve months ended 31 December 2023 (unaudited)
    6-K
  9. Three months ended 30 September 2023
    6-K
  10. Six months ended 30 June 2023 (unaudited)
    6-K
  11. months ended 31 March 2023
    6-K
  12. Haleon plc (the “Company”) (LSE/NYSE: HLN) today provides the following update ahead of the Annual General Meeting (AGM).
    6-K
  13. This press release shall not constitute an
    6-K
  14. Twelve months ended 31 December 2022 (unaudited)
    6-K
  15. John will be succeeded as Non-Executive Director and representative of Pfizer by David Denton with effect from 1 March
    6-K